JP2023503858A5 - - Google Patents
Info
- Publication number
- JP2023503858A5 JP2023503858A5 JP2022528249A JP2022528249A JP2023503858A5 JP 2023503858 A5 JP2023503858 A5 JP 2023503858A5 JP 2022528249 A JP2022528249 A JP 2022528249A JP 2022528249 A JP2022528249 A JP 2022528249A JP 2023503858 A5 JP2023503858 A5 JP 2023503858A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- mva
- nucleic acid
- acid encoding
- taa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19210369.5 | 2019-11-20 | ||
| EP19210369 | 2019-11-20 | ||
| EP20191226.8 | 2020-08-14 | ||
| EP20191226 | 2020-08-14 | ||
| EP20193706.7 | 2020-08-31 | ||
| EP20193706 | 2020-08-31 | ||
| PCT/EP2020/082888 WO2021099572A1 (en) | 2019-11-20 | 2020-11-20 | Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023503858A JP2023503858A (ja) | 2023-02-01 |
| JP2023503858A5 true JP2023503858A5 (enExample) | 2023-10-26 |
| JP7670705B2 JP7670705B2 (ja) | 2025-04-30 |
Family
ID=73455743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528249A Active JP7670705B2 (ja) | 2019-11-20 | 2020-11-20 | ４－１ｂｂｌアジュバント添加した組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）の医学的使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230059344A1 (enExample) |
| EP (1) | EP4061404A1 (enExample) |
| JP (1) | JP7670705B2 (enExample) |
| KR (1) | KR20220116191A (enExample) |
| CN (1) | CN114929268A (enExample) |
| AU (1) | AU2020388973A1 (enExample) |
| BR (1) | BR112022009797A2 (enExample) |
| CA (1) | CA3159666A1 (enExample) |
| IL (1) | IL293012A (enExample) |
| MX (1) | MX2022005601A (enExample) |
| WO (1) | WO2021099572A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050790B (zh) * | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| US12194157B2 (en) | 2020-04-09 | 2025-01-14 | Finncure Oy | Carrier for targeted delivery to a host |
| FI20215508A1 (en) | 2020-04-09 | 2021-10-10 | Niemelae Erik Johan | Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection |
| CN117004579B (zh) * | 2023-06-29 | 2024-11-15 | 苏州恩立维生物科技有限公司 | 重组溶瘤牛痘病毒及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| US8691502B2 (en) * | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| MX367100B (es) * | 2012-02-17 | 2019-08-05 | The Children´S Hospital Of Philadelphia | Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos. |
| WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| CA2942501A1 (en) * | 2014-03-17 | 2015-09-24 | Tapimmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
| KR102499737B1 (ko) * | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| WO2017120577A1 (en) | 2016-01-08 | 2017-07-13 | Geovax Inc. | Compositions and methods for generating an immune response to a tumor associated antigen |
| IL261321B2 (en) * | 2016-02-25 | 2023-12-01 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| WO2017152042A2 (en) * | 2016-03-04 | 2017-09-08 | New York University | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity |
| CN111050790B (zh) | 2017-08-24 | 2024-07-12 | 巴法里安诺迪克有限公司 | 通过静脉内施用重组mva和抗体治疗癌症的组合疗法 |
| US20190345516A1 (en) * | 2018-03-12 | 2019-11-14 | Musc Foundation For Research Development | Methods for treating eye disease |
| CA3119503A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
-
2020
- 2020-11-20 IL IL293012A patent/IL293012A/en unknown
- 2020-11-20 EP EP20808119.0A patent/EP4061404A1/en active Pending
- 2020-11-20 JP JP2022528249A patent/JP7670705B2/ja active Active
- 2020-11-20 WO PCT/EP2020/082888 patent/WO2021099572A1/en not_active Ceased
- 2020-11-20 MX MX2022005601A patent/MX2022005601A/es unknown
- 2020-11-20 CN CN202080092410.7A patent/CN114929268A/zh active Pending
- 2020-11-20 BR BR112022009797A patent/BR112022009797A2/pt unknown
- 2020-11-20 AU AU2020388973A patent/AU2020388973A1/en active Pending
- 2020-11-20 US US17/778,398 patent/US20230059344A1/en active Pending
- 2020-11-20 CA CA3159666A patent/CA3159666A1/en active Pending
- 2020-11-20 KR KR1020227020948A patent/KR20220116191A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023503858A5 (enExample) | ||
| Gulley et al. | Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma | |
| JP2022507744A5 (enExample) | ||
| Zhao et al. | Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment | |
| Vergati et al. | Strategies for cancer vaccine development | |
| Bilusic et al. | Immunotherapy of prostate cancer: facts and hopes | |
| Madan et al. | Clinical evaluation of TRICOM vector therapeutic cancer vaccines | |
| Heery et al. | Phase I study of a poxviral TRICOM-based vaccine directed against the transcription factor brachyury | |
| DeMaria et al. | Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer | |
| JP2017515841A5 (enExample) | ||
| JP2017515837A5 (enExample) | ||
| JP2012524075A5 (enExample) | ||
| JP2023503857A5 (enExample) | ||
| Ma et al. | Development of tumour peptide vaccines: From universalization to personalization | |
| Pol et al. | Trial Watch: DNA vaccines for cancer therapy | |
| US20160017011A1 (en) | Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy | |
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| ASGHARI et al. | Hsp70 in cancer: partner or traitor to immune system | |
| JP2022538609A5 (enExample) | ||
| Li et al. | Challenges and exploration for immunotherapies targeting cold colorectal cancer | |
| Zhao et al. | A nanobody–bioorthogonal catalyst conjugate triggers spatially confined prodrug activation for combinational chemo-immunotherapy | |
| Boehm et al. | Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations | |
| JP2022539585A5 (enExample) | ||
| CN119770632A (zh) | 诱导免疫应答的组合物和方法 | |
| Chang et al. | Metabolism profiles of tannins in Phyllanthus emblica L. and its immunotherapeutic potential against hepatocellular carcinoma by re-educating tumor microenvironment |